In 2020, U.K.-based Exscientia and its partner, Japan-based Sumitomo Pharma, announced the first AI-created drug would enter a phase 1 trial for obsessive-compulsive disorder. Two years later, Sumitomo ended the research because the drug failed to meet study criteria.
In the last three and a half years, two other companies have started and ended clinical trials for drug candidates made by AI, according to Endpoints News. A bandwagon of AI hype formed when the research was made public, but the trend seems to be turning into a fad after the three companies worked for about a decade to research and develop these therapies.
In the biotech industry, only about 5% to 10% of medications tested in human trials make it to the market. The fanfare for AI-fashioned drugs couldn’t make this low statistic budge.
“If you take the hype and PR at face value over the last 10 years, you would think it goes from 5% to 90%,” Patrick Malone, MD, PhD, a principal at science investment firm KdT Ventures, told Endpoints News. “But if you know how these models work, it goes from 5% to maybe 6% or 7%.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
